NEW YORK (GenomeWeb News) – Nanosphere today posted a 56 percent slide in first-quarter revenues that it attributed to delays in regulatory clearance for its new products.

The company reported total revenue of $255,000 for the three-month period ended March 31, 2009, compared to $576,000 in the prior-year period.

For the first quarter of 2009, all of the company's revenues were from product sales. For the prior-year quarter, Nanosphere reported $303,000 in product sales and approximately $273,000 from government grants and contracts.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.